Eicosapentaenoic
Eicosapentaenoic Brand names, Eicosapentaenoic Analogs
Eicosapentaenoic Brand Names Mixture
- No information avaliable
Eicosapentaenoic Chemical_Formula
C20H30O2
Eicosapentaenoic RX_link
No information avaliable
Eicosapentaenoic fda sheet
Eicosapentaenoic msds (material safety sheet)
Eicosapentaenoic Synthesis Reference
No information avaliable
Eicosapentaenoic Molecular Weight
302.456 g/mol
Eicosapentaenoic Melting Point
No information avaliable
Eicosapentaenoic H2O Solubility
No information avaliable
Eicosapentaenoic State
Oily Liquid
Eicosapentaenoic LogP
6.23 +/- 0.48
Eicosapentaenoic Dosage Forms
Capsule (usually in fish oil in a combination with DHA)
Eicosapentaenoic Indication
EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.
Eicosapentaenoic Pharmacology
Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.
Eicosapentaenoic Absorption
No information avaliable
Eicosapentaenoic side effects and Toxicity
No information avaliable
Eicosapentaenoic Patient Information
No information avaliable
Eicosapentaenoic Organisms Affected
No information avaliable
